@florshamb_boutique: Un diseño lleno de color, elegancia y personalidad para destacar con estilo. 🩷🖤✨ 👗FLOR SHAMB BOUTIQUE 📲 093 993 8188 📍Edmundo Carvajal y El Cóndor, al Norte de QUITO #conjuntosfemininos #ropamujer #fyp #videoviral #quito_ecuador🇪🇨

Flor Shamb Boutique
Flor Shamb Boutique
Open In TikTok:
Region: EC
Tuesday 14 July 2026 02:17:26 GMT
11440
255
18
45

Music

Download

Comments

user69249410421345
claudia :
Disculpe si tiene talla L y otros colores
2026-07-14 02:39:40
1
laurachisaguano
Lauri flor :
me encanta
2026-08-20 11:09:32
1
carmentoloza3
carmentoloza3 :
hola estan lindo tiene en xxxxl
2026-07-27 17:30:46
1
ivonne.huayamave
Ivonne Huayamave :
Precio del vestido
2026-08-13 17:55:57
1
geraniorivera
norma eliza :
precio talla L o Xl
2026-08-13 19:30:09
1
jaquelinecastillo293
jaquelinecastillo293 :
Qué hermoso vestido
2026-07-14 12:18:57
1
ruth.jovita.robay
RUTH JOVITA ROBAYO JACOME :
di mehusta
2026-07-14 20:38:46
1
narcisadejesuscal
Alex :
precio gracias para envío Ambato
2026-08-04 15:05:18
0
monicasolanocisneros
MonicaSolanoCisneros :
🥰🥰🥰
2026-07-14 22:19:08
1
To see more videos from user @florshamb_boutique, please go to the Tikwm homepage.

Other Videos

Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close.   Note: I have not been compensated in any way for this post/interview.  #Foundayo #newGLP-1 #GLP-1pill #EliLilly
Big news in the world of Obesity Medicine and weight management today, and I want to make sure you actually understand what it means, not just that it happened. The FDA just approved Foundayo (orforglipron), Eli Lilly's once-daily GLP-1 pill for obesity, and it's worth paying attention to. Here's what you need to know: The clinical data: In the Phase 3 ATTAIN trials, patients lost an average of 12.4% of their body weight at the highest dose over 72 weeks. Real, meaningful weight loss. Less than Zepbound's ~21%, but this isn't a shot. It's a pill. The access piece: With commercial insurance, eligible patients could pay as little as $25/month. Self-pay starts at $149. Medicare Part D coverage could begin as early as July at $50/month. For a category where people have been paying $1,000+/month, that matters enormously. The practical difference: Unlike the Wegovy pill, which requires an empty stomach and a 30-minute wait, Foundayo can be taken any time, no food or water restrictions. Side effects: Same GI profile as the rest of this class. The thyroid cancer warning is there too, so if you have a history of medullary thyroid carcinoma, this isn't for you. Is it a replacement for the injectables? No. A legitimate option for people who want oral medication, or an oral maintenance strategy after hitting goal weight? Yes. I sat down one on one with Dave Ricks, CEO of Eli Lilly. That interview is coming, and I think it'll change how you think about where this whole category is headed. Stay close. Note: I have not been compensated in any way for this post/interview. #Foundayo #newGLP-1 #GLP-1pill #EliLilly

About